Is CVS Health Stock (CVS) a Buy Ahead of Earnings?
Leerink Partners Maintains CVS Health(CVS.US) With Buy Rating, Raises Target Price to $79
CVS Health Positioned for Growth: Buy Rating Affirmed Amid Earnings Recovery and Strategic Improvements
TD Cowen Maintains CVS Health(CVS.US) With Buy Rating, Raises Target Price to $90
Morgan Stanley Maintains CVS Health(CVS.US) With Buy Rating, Raises Target Price to $80
Baird Maintains CVS Health(CVS.US) With Hold Rating, Raises Target Price to $71
Morgan Stanley Adjusts Price Target on CVS Health to $80 From $68, Maintains Overweight Rating
CVS Health Price Target Raised to $71.00/Share From $51.00 by Baird
CVS Health Is Maintained at Neutral by Baird
CVS Health Analyst Ratings
Truist Financial Maintains CVS Health(CVS.US) With Buy Rating, Announces Target Price $82
Truist Securities Adjusts Price Target on CVS Health to $82 From $76, Keeps Buy Rating
Mizuho Securities Maintains CVS Health(CVS.US) With Buy Rating, Raises Target Price to $76
Truist Financial Maintains CVS Health(CVS.US) With Buy Rating
A Quick Look at Today's Ratings for CVS Health(CVS.US), With a Forecast Between $71 to $80
CVS Health Analyst Ratings
Mizuho Maintains Outperform on CVS Health, Raises Price Target to $76
Analysts Have Conflicting Sentiments on These Healthcare Companies: CVS Health (CVS) and BioNano Genomics (BNGO)
TD Cowen Maintains CVS Health(CVS.US) With Buy Rating, Maintains Target Price $80
TD Cowen Keeps Their Buy Rating on CVS Health (CVS)